Senexis Ltd has developed a series of "meptides" (N-methylated peptides) that block the aggregation of β-amyloid. Cresset was asked to find novel series of non-peptide small molecules with different physico-chemical properties from the "meptides". Result: Two active chemotypes with new scaffolds.
Please click here.

To view the full case study please click here.